MYVAL, a TAVR Balloon-Expandable Valve with Promising Results

TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker. 

MYVAL, una válvula balón expandible para TAVI con resultados alentadores

This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril Life Sciences Pvt. Ltd.  

Patient mean age was 74, and they were mostly men. 95 participants were hypertensive, 40 diabetic, and most were in functional class II-III; 24 had prior MI, 22 prior CABG, 8 prior stroke, 9 were in need of a pacemaker and 18 presented atrial fibrillation. 17 cases had bicuspid valve. Ejection fraction was 55%.

Mortality STS score was 4.8%.

99 cases were treated with a transfemoral approach and 97 received conscious sedation. 

Read also: EVOQUE: Transcatheter Tricuspid Valve Replacement, One-Year Outcomes.

Device implantation was successful in 99 patients. 

At 30 days, there was one death, one stroke, five major bleeding events, and six major vascular complications., three cases of kidney function deterioration and 28 patients needed a pacemaker.

After 12 months, there were seven cases of all-cause mortality, five strokes, two endocarditis, one valve dysfunction requiring surgery and one hospitalization for cardiac failure. All patients experienced functional class improvement. 

Read also: New Advances in Mitral Regurgitation Devices with Promising Results.

ECG analysis showed mean gradient 9.5 mmHg, with no significant differences between bicuspid and tricuspid valves. Left ventricular ejection fraction was 59%, and no patient presented moderate or severe leaks. 

Conclusion

TAVR with Myval showed excellent results at 30 days and one year, considering technical success, survival and valve related events. We should take into account the limitations of this analysis, based on retrospectively gathered data from one single center. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Single center experience with the balloon‐expandable Myval transcatheter aortic valve system with the first 100 patients: 30‐day and 1‐year follow‐up. 

Reference: Balázs Magyari, et al. Catheter Cardiovasc Interv. 2023;102:1317–1330. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology


More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...